Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

62.96USD
23 Sep 2016
Change (% chg)

$-0.06 (-0.10%)
Prev Close
$63.02
Open
$62.87
Day's High
$63.25
Day's Low
$62.70
Volume
7,679,801
Avg. Vol
9,541,882
52-wk High
$64.00
52-wk Low
$47.97

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $174,097.50
Shares Outstanding(Mil.): 2,765.21
Dividend: 0.46
Yield (%): 2.92

Financials

  MRK Industry Sector
P/E (TTM): 34.49 36.61 36.60
EPS (TTM): 1.83 -- --
ROI: 6.19 14.46 13.91
ROE: 11.43 15.26 14.82

Bayer raises sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

Sep 20 2016

UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal

* Bayer shares seen 1.5 pct higher (Adds consumer care unit target, analyst comment, premarket share price)

Sep 20 2016

BRIEF-Bayer says Merck & Co integration disrupts business more than expected

* Bayer says had underestimated risk from emerging markets volatility related to purchase of merck & co consumer care business

Sep 20 2016

BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar

* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar

Sep 19 2016

BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis

* Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis

Sep 16 2016

BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint

* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes

Sep 15 2016

BRIEF-Aralez acquires U.S., Canadian rights to Zontivity from Merck

* Aralez acquires united states and canadian rights to Zontivity from Merck

Sep 07 2016

Merck scraps development of osteoporosis drug due to stroke risk

Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

Sep 02 2016

UPDATE 1-Merck scraps development of osteoporosis drug due to stroke risk

Sept 2 Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

Sep 02 2016

BRIEF-Merck provides update on odanacatib development program

* To discontinue development after independent adjudication of major adverse cardiovascular events confirmed an increased risk of stroke

Sep 02 2016

Competitors

Earnings vs. Estimates